S. Koul

发表

Characteristic promoter hypermethylation signatures in male germ cell tumors

V. Reuter, M. Mansukhani, J. McKiernan, 2002, Molecular Cancer.

Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes.

R. Kucherlapati, V. Reuter, F. Naef, 2002, Cancer research.

Upregulation of BMI1-suppressor miRNAs (miR-200c, miR-203) during terminal differentiation of colon epithelial cells

D. Sahoo, K. Lao, Y. Kakeji, 2022, Journal of Gastroenterology.

High throughput and low bias DNA methylation and hydroxymethylation analysis by direct injection mass spectrometry.

M. Brenowitz, S. Sidoli, S. Garforth, 2021, Analytica chimica acta.

Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors

J. Bacik, V. Reuter, M. Mansukhani, 2004, Molecular Cancer.

Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human Mantle Cell Lymphoma (MCL) cells

K. Bhalla, S. Upadhyay, Yonghua Yang, 2009, Cancer biology & therapy.

Genetic analysis identifies putative tumor suppressor sites at 2q35–q36.1 and 2q36.3–q37.1 involved in cervical cancer progression

M. Mansukhani, P. Rao, M. Terry, 2003, Oncogene.

Mapping the sites of putative tumor suppressor genes at 6p25 and 6p21.3 in cervical carcinoma: occurrence of allelic deletions in precancerous lesions.

A. Chatterjee, V. Murty, H. Posso, 2001, Cancer research.

Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

P. Atadja, K. Bhalla, S. Upadhyay, 2009, Cancer biology & therapy.

Frequent Promoter Methylation of CDH1, DAPK, RARB, and HIC1 Genes in Carcinoma of Cervix Uteri: Its Relationship to Clinical Outcome

M. Mansukhani, M. Terry, Fang F. Zhang, 2003, Molecular Cancer.

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

Huidong Shi, P. Atadja, K. Bhalla, 2009, Blood.

Mouse Models of Germinal Center Derived B-Cell Lymphomas

L. Pasqualucci, S. Koul, Stefanie N. Meyer, 2021, Frontiers in Immunology.

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.

Yufeng Shen, A. Borczuk, B. Halmos, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.

Z. Cournia, A. Efstratiadis, A. Klinakis, 2014, Journal of the National Cancer Institute.

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

P. Atadja, R. Levine, K. Bhalla, 2009, Blood.

AXL kinase as a novel target for cancer therapy

B. Halmos, Zhenfeng Zhang, C. Lee, 2014, Oncotarget.

Physical characterization of a glucose-dehydrogenase-bearing plasmid from ketoacid-producingErwinia herbicola

V. Verma, G. N. Qazi, S. Johri, 1995, World Journal of Microbiology & Biotechnology.

Detection of frequent MET Exon 14 skipping events in pulmonary sarcomatoid carcinoma and response to targeted inhibition.

Yufeng Shen, A. Borczuk, B. Halmos, 2015 .

PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling

A. Borczuk, B. Halmos, R. Ohki, 2015, Oncotarget.

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.

Huidong Shi, P. Atadja, K. Bhalla, 2009, Blood.

AXL kinase as a novel target for cancer therapy

B. Halmos, Zhenfeng Zhang, C. Lee, 2014, Oncotarget.